The FDA now requires the bottle labeling or prescribing information for nonsteroidal anti-inflammatory drugs to disclose the risks associated with their use in people who are pregnant, the agency announced Oct. 15.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,